Literature DB >> 12198627

Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis.

James I Ito1, Joseph M Lyons.   

Abstract

Invasive pulmonary aspergillosis is an emerging devastating infection in the immunocompromised host that is treated with corticosteroids for neoplastic disease or for organ transplantation. By use of a model of invasive pulmonary aspergillosis in corticosteroid-treated CF-1 mice, prior infection and 2 Aspergillus fumigatus vaccine preparations (sonicate and filtrate) administered intranasally and subcutaneously were tested for efficacy in protecting against subsequent lethal A. fumigatus infection. The mortality rates were as follows: control subjects, 100%; prior infection, 12.5%; sonicate administered intranasally, 29%; sonicate given subcutaneously, 0%; filtrate given intranasally, 75%; and filtrate given subcutaneously, 50%. Prior infection and A. fumigatus sonicate vaccine administered by 2 routes protected corticosteroid-treated animals against subsequent lethal invasive pulmonary aspergillosis. The sonicate vaccine was more protective, but the subcutaneous route was more effective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12198627     DOI: 10.1086/342509

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

Authors:  James I Ito; Joseph M Lyons; Teresa B Hong; Daniel Tamae; Yi-Kuang Liu; Sharon P Wilczynski; Markus Kalkum
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

Review 2.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

3.  CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine.

Authors:  Diana Diaz-Arevalo; Karine Bagramyan; Teresa B Hong; James I Ito; Markus Kalkum
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

4.  Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy.

Authors:  I D Jacobsen; S Brunke; K Seider; T Schwarzmüller; A Firon; C d'Enfért; K Kuchler; B Hube
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

Review 5.  Current and future therapeutic options in the management of invasive aspergillosis.

Authors:  Suganthini Krishnan-Natesan; Pranatharthi H Chandrasekar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Vaccines for invasive fungal infections.

Authors:  Brad Spellberg
Journal:  F1000 Med Rep       Date:  2011-07-01

7.  Epidemiology and treatment approaches in management of invasive fungal infections.

Authors:  Jane Kriengkauykiat; James I Ito; Sanjeet S Dadwal
Journal:  Clin Epidemiol       Date:  2011-05-19       Impact factor: 4.790

8.  Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins.

Authors:  Jackson Champer; James I Ito; Karl V Clemons; David A Stevens; Markus Kalkum
Journal:  J Fungi (Basel)       Date:  2016-01-12

9.  Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals.

Authors:  Roberta Gaziano; Silvia Bozza; Silvia Bellocchio; Katia Perruccio; Claudia Montagnoli; Lucia Pitzurra; Giovanni Salvatori; Rita De Santis; Paolo Carminati; Alberto Mantovani; Luigina Romani
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 10.  New insights on the development of fungal vaccines: from immunity to recent challenges.

Authors:  Natasha P Medici; Maurizio Del Poeta
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11-24       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.